[Click eStock] "i-SENS to Launch COVID-19 Antibody Diagnostic Device Within the Year"

[Asia Economy Reporter Jang Hyowon] Research Alume analyzed on the 28th that i-SENS is expected to see additional performance improvement in the second half of this year with the launch of a novel coronavirus (COVID-19) antibody diagnostic device. The target price was suggested at 42,000 KRW.

Senior Researcher Choi Seonghwan stated in the report, "i-SENS is the number one company in the domestic self-blood glucose monitoring device market and continues stable growth due to the increase in diabetic patients," adding, "Along with the stability of its core business, the launch of the COVID-19 antibody diagnostic device within this year is expected to bring additional performance improvement in the second half."

i-SENS plans to launch the COVID-19 antibody measuring device in the fourth quarter of this year. It has already signed contracts with renowned hospitals in the United States and has begun full-scale sales after clinical trials.

Senior Researcher Choi said, "Next year, through the launch of a continuous glucose monitoring device, it is expected to secure long-term growth momentum," and added, "Since health insurance coverage for continuous glucose monitoring devices has been implemented since January this year, a positive impact is anticipated."

He forecasted that i-SENS's consolidated sales for this year will be 217.2 billion KRW and operating profit will be 35.6 billion KRW, representing increases of 14.4% and 18%, respectively, compared to the previous year.

He explained, "Stable growth in the core self-blood glucose monitoring device business and sales of the COVID-19 antibody diagnostic device launched in the second half have secured additional growth momentum."